Search

Corvus Pharmaceuticals Inc

Uždarymo kaina

12.63 0.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.43

Max

13.11

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-4.3M

-18M

Pelnas, tenkantis vienai akcijai

-0.19

Darbuotojai

37

EBITDA

-5.3M

-17M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+125.02% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-21M

1.1B

Ankstesnė atidarymo kaina

12.39

Ankstesnė uždarymo kaina

12.63

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-15 23:56; UTC

Akebia Therapeutics Inc shares are higher in after-market trading. Broader market sentiment is affected by a sharp decline in the NY Empire State Manufacturing Index.

2026-09-15 23:56; UTC

Fastly Inc. shares declined after-market, influenced by negative sentiment from the NY Empire State Manufacturing Index's sharp fall. The stock settled lower after a brief recovery.

2026-09-15 23:56; UTC

News

Lululemon Athletica shares are lower in after-market hours amid an investigation into potential securities law violations following a revenue guidance cut.

2026-09-15 23:56; UTC

eHealth Inc. shares were little changed in after-market hours. Broader market sentiment weakened following a significant decline in the NY Empire State Manufacturing Index.

2026-09-15 23:56; UTC

Maxlinear Inc shares are lower in after-market hours, pressured by a sharp decline in the NY Empire State Manufacturing Index, raising economic concerns.

2026-09-15 23:56; UTC

DaVita Inc shares are lower in after-market trading amid negative sentiment following a sharp decline in the NY Empire State Manufacturing Index.

2026-09-15 23:56; UTC

Textron Inc shares are higher in after-market trading, reaching a peak gain following the NY Empire State Manufacturing Index's sharp decline to 7.6 for September.

2026-09-15 23:56; UTC

Bandwidth Inc. shares declined in after-market hours, reflecting negative sentiment tied to a sharp drop in the NY Empire State Manufacturing Index.

2026-09-15 23:52; UTC

Japan's August trade deficit hits -1052.6 billion yen amid ongoing economic challenges and weak yen concerns, raising questions on future monetary policy.

2026-09-15 23:52; UTC

Japan's Exports Expected to Rise 0.182% YoY Amid Cautious Optimism in Global Trade Dynamics

2026-09-15 23:52; UTC

Japan's Machinery Orders Expected to Decline by 2.8% in September, Raising Concerns Over Capital Spending and Business Investment

2026-09-15 23:52; UTC

US Business Inventories MoM Data Release on September 16 Expected to Show Modest 0.3% Increase Amid Inflation and Interest Rate Concerns.

2026-09-15 23:52; UTC

Brazil's Central Bank to announce interest rate decisions on September 21, amid global focus on central bank policies and inflation concerns.

2026-09-15 23:52; UTC

NAHB Housing Market Index for September 2026 Expected at 34.0 Amid Ongoing Builder Confidence Concerns and Slowing Home Construction

2026-09-15 23:52; UTC

U.S. Industrial Production Expected to Rise 0.3% in September Amid Mixed Economic Signals and Global Concerns

2026-09-15 23:51; UTC

Innovative Industrial Properties Inc shares are higher in after-market hours, though no specific company news was identified to explain the movement.

2026-09-15 23:51; UTC

Box Inc shares are higher in after-market hours, continuing a trend of higher closes over the last three sessions. No specific news was identified.

2026-09-15 23:51; UTC

Correlated Moves

Shares of Sunrun Inc. declined in after-market trading, diverging from recent trends amid mixed economic data and rising U.S. crude oil inventories.

2026-09-15 23:51; UTC

Progressive Corp shares declined during after-market hours, reaching a low of -0.61%. No specific news was identified to explain the price movement.

2026-09-15 23:51; UTC

Correlated Moves

Ross Stores Inc shares are higher in after-market trading, reflecting positive sentiment linked to TJX Companies Inc's performance amid increased after-hours activity.

2026-09-15 23:51; UTC

CytomX Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. This marks a shift from recent trends.

2026-09-15 23:51; UTC

Under Armour Inc shares are lower in after-market trading, continuing declines amid inflation concerns linked to rising U.S. crude oil inventories.

2026-09-15 23:51; UTC

Minerals Technologies Inc shares are lower in after-market hours, with no specific news identified. The stock remains below its 20-day moving average.

2026-09-15 23:51; UTC

Editas Medicine Inc shares are higher in after-market trading. No specific company news was identified to explain this price movement.

2026-09-15 23:51; UTC

Correlated Moves

Raymond James Financial shares are higher in after-market trading, aligning with Bank of America's performance despite mixed broader market sentiment.

2026-09-15 23:51; UTC

T-Mobile US Inc shares are higher in after-market hours, continuing a recent upward trend from earlier lows. No specific news was identified for the movement.

2026-09-15 23:46; UTC

Insight Enterprises Inc shares are higher in after-market trading, advancing slightly since Tuesday's close. The stock is positioned above its 20-day moving average.

2026-09-15 23:46; UTC

California Water Service Group shares were roughly flat in after-market hours, remaining about 3.74% below their 20-day moving average.

2026-09-15 23:46; UTC

LeMaitre Vascular Inc. shares are higher in after-market trading, moving within a narrow range since Tuesday's close and remaining near the lower end of their monthly range.

2026-09-15 23:46; UTC

Essential Utilities Inc shares are higher in after-market hours, remaining near the upper end of their one-month trading range. No specific news was identified.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

125.02% į viršų

12 mėnesių prognozė

Vidutinis 29.5 USD  125.02%

Aukščiausias 33 USD

Žemiausias 27 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat